Analytical Data
-
Gene name
CD300a/LMIR1
-
简介
CD300a/LMIR1 protein inhibits cytolytic activity in NK cells and mast cell degranulation. It negatively regulates TLR signaling via MYD88 and PTPN6 activation, but not TRIF. CD300a/LMIR1 interacts with PTN6/SHP-1, PTPN11/SHP-2, and INPP5D upon tyrosine phosphorylation. CD300a/LMIR1 Protein, Mouse (HEK293, Fc) is the recombinant mouse-derived CD300a/LMIR1 protein, expressed by HEK293 , with C-hFc labeled tag.
- Application
-
Alternative Names
CMRF35-like molecule 8; CLM-8; MAIR-1; CD300a
-
Species
Mouse
-
Source
HEK293
-
Tag
C-hFc
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q6SJQ0-1
-
Expression Region
L28-R183
-
Protein Length
Extracellular Domain
-
Molecular Weight
58-75 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CD300a, also known as LMIR1 (Leukocyte Immunoglobulin-Like Receptor 1), is an immune receptor belonging to the CD300 family, which plays a critical role in the regulation of immune responses. The study of CD300a/LMIR1 has gained significant attention due to its involvement in modulating the activity of various immune cells, including T cells, dendritic cells, and macrophages. This receptor has been shown to interact with phosphatidylserine and other ligands, leading to the suppression of inflammatory responses and promotion of immune tolerance. Research has indicated that CD300a can influence the development and function of regulatory T cells, thereby impacting the balance between immune activation and inhibition. Given its potential implications in autoimmune diseases, cancer, and transplantation, CD300a/LMIR1 is considered a promising target for therapeutic intervention. The generation and characterization of recombinant CD300a proteins provide valuable tools for understanding the receptor’s functional mechanisms and exploring its role in immune regulation. Studying these proteins can pave the way for the development of novel strategies to modulate immune responses in various clinical settings, enhancing our ability to treat immune-related disorders effectively.
